Actionable news
All posts from Actionable news
Actionable news in ZGNX: Zogenix, Inc.,

Oppenheimer Reiterates Outperform on Zogenix, Inc. Following IND Update


In a research report issued yesterday, Oppenheimer analyst Akiva Felt reiterated an Outperform rating on shares of Zogenix, Inc. (NASDAQ:ZGNX) with a price target of $23, after the company announced that it received a request from the FDA for additional information pertaining to its Investigational New Drug application with the product ZX008, for the treatment of Dravet syndrome.

Felt wrote, “Given sector skittishness recently, the press release (PR) on ZX008 IND filing may cause investors to worry that something is amiss, but we strongly believe the update itself is benign. We spoke to...